In the rapidly changing tobacco industry,
22nd Century Group, Inc. ($XXII) is emerging as a pioneer with its innovative approach to smoking alternatives. The company has gained significant attention for its
VLN® cigarettes, the world’s first combustible cigarette to receive the
Modified Risk Tobacco Product (MRTP) designation from the U.S. Food and Drug Administration (FDA). This achievement positions 22nd Century as a potential leader in providing safer smoking options.
VLN® cigarettes contain up to 95% less nicotine than traditional cigarettes, offering adult smokers a groundbreaking option to reduce nicotine consumption or quit altogether. This aligns with public health goals to minimize tobacco-related harm. The FDA’s MRTP designation acknowledges VLN® as a product that can benefit public health by reducing the risk of nicotine addiction, promoting safer smoking alternatives.
The company's mission, "to sell the last cigarette before the 22nd Century," underscores its dedication to transitioning smokers toward reduced-risk products. With a focus on harm reduction, 22nd Century is positioning itself at the forefront of the global shift towards more responsible tobacco use, appealing to both health-conscious consumers and forward-thinking investors.